Physician profile
Julia Larocca
NPI 1972978690
$2,007.72
in general payments reported to CMS, 2019-2025
22 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $679 · 2022: $445 · 2023: $409 · 2024: $261 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $799.30 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $212.38 | 2021-2022 | |
| Novo Nordisk INC | $156.45 | 2021-2025 | Rybelsus, Ozempic |
| Galderma Laboratories, L.P. | $115.48 | 2021-2023 | Dysport |
| Amgen INC. | $96.79 | 2022-2023 | Repatha, Otezla |
| Lilly USA, LLC | $86.72 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Almatica Pharma LLC | $69.79 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $69.31 | 2023-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $65.98 | 2021-2024 | Veozah |
| Glaxosmithkline, LLC. | $65.17 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Xeris Pharmaceuticals, INC. | $40.75 | 2023 | Keveyis, Gvoke Hypopen |
| Lundbeck LLC | $37.04 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $30.47 | 2024-2025 | Breztri, Airsupra |
| Revance Therapeutics, INC. | $29.14 | 2025 | Daxxify |
| Genentech USA, INC. | $20.29 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19.64 | 2021 | |
| Pfizer INC. | $18.12 | 2023 | |
| Exact Sciences Corporation | $17.72 | 2025 | Cologuard Collection Kit |
| Genzyme Corporation | $16.73 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $14.96 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.14 | 2023 | Quviviq |
| Allergan, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Larocca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.